MAPKAPK5

Across TCGA pan-cancer cohorts, MAPKAPK5 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAPKAPK5 data layer compared with 27 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher MAPKAPK5 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAPKAPK5 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where MAPKAPK5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Tertile	All	0.869	0.214	<.001	38	view →
HNSC	DFS	Tertile	II,III,IV	0.574	0.990	.005	24	view →
LUAD	DFS	Quartile	III,IV	0.939	0.488	.006	9	view →
UCEC	DFS	Median	III,IV	1.000	0.527	.049	4	view →
GBM	DFS	Median	All	0.206	0.441	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MAPKAPK5–LSCC (DFS)

Open the LSCC breakdown →